Life Sciences & Healthcare
In a dynamic environment where changing regulatory requirements, long product cycles, complex intellectual property rights and cost pressure on healthcare pose constant challenges for our clients, we offer you access to our extensive team of savvy experts. Not only are they legally qualified; they also have a deep understanding of the relevant technical and business-related issues in the life sciences and healthcare sectors.
Life Sciences is a key consulting area for our firm, where we have special expertise and proven track record, providing you with comprehensive support with pharmaceuticals, biotech, healthcare, medtech and digital health.
Areas of Expertise
Our specialists can advise you in the following areas in particular:
- Developing intellectual property strategies, patent management and exploitation of intellectual property rights, supplementary protection certificates and extensions of paediatric rights; freedom-to-operate investigations;
- National and cross-border M&A and private equity transactions and financing for pharmaceutical, biotech, healthcare and medtech companies as well as structuring and implementing joint ventures and other cooperation agreements;
- Hospital financing and cooperations;
- Distribution and supply agreements, cooperation agreements, license agreements, manufacturing agreements, research and development agreements, employee invention agreements;
- Patent litigation (infringement proceedings, invalidity proceedings, assignment and ownership disputes, licensing disputes);
- Other commercial arbitration and litigation in the field of life sciences and health care;
- Regulatory advice and compliance regarding the Therapeutic Products Act (regulatory data protection, advice on pharmaceutical products, cooperations with HCPs and HCOs etc.);
- Advertising law regarding therapeutic products, trademark law and other labelling issues regarding pharmaceuticals, biotech and medtech;
- Pricing of therapeutic products and representation before the Federal Office of Public Health
- Competition law advice (price differentiation, distribution channel planning etc.);
- E-health, data management, data protection strategies, advice in connection with digital business ideas and online platforms;
- Outsourcing projects;
- Product recall procedures
Team
- Renato Bucher
- Lukas Bühlmann
- Ulrike Ciesla
- Frédéric Cottier
- Louisa Galbraith
- Kevin M. Hubacher
- Markus Frank Huber
- L. Mattias Johnson
- Mark Montanari
- Michael Reinle
- Michael Ritscher
- Marc A. Schamaun
- Daniel Schoch
- Peter Schramm
- Kilian Schärli
- Andrea Sieber
- Mona Stephenson
- Hélène Weidmann
- Julie Wynne
- Nadine von Büren-Maier
- Daniel Donauer
- Philipp Estermann
- Andrea Heiniger
- Bettina Klein
- Noemi Bünter
- Ada Sofie Altobelli
- Andreas Bossard
- Nadia Fiechter
- Marc Fiorellino
- Marzella Grando
- Luca Henn
- Maša Kojic
- Mladen Naskovic
- Cédric Saladin
- Dominic Schopf
- Franziska Schweizer
- Jutta Triches
“When litigating patents in Switzerland, only a handful of top drawer names come to mind, and MLL stands out. A fabulous team of partners and associates, all punching above their weights and delivering fantastic results for clients”
Publications
Swiss Federal Supreme Court confirms validity of Bristol-Myers Squibb’s SPC for apixaban
Bristol-Myers Squibb successfully defended the Swiss SPC for the pharmaceutical active ingredient apixaban, used in the blockbuster anticoagulant Eliquis.- EN
Das Täuschungsverbot im schweizerischen Lebensmittel- und Gebrauchsgegenständerecht
Kommentierung der täuschungsrechtlichen Vorgaben zu den Lebensmitteln, Bedarfsgegenständen und kosmetischen Mitteln, www.jusletter.ch, jusletter.weblaw.ch, Weblaw AG- DE
- Daniel Donauer
- Pranvera Rasaj
- Noëlle Ulrich
Die Vermarktung von Kosmetika – Regulatorische Vorgaben in der Schweiz und der EU
Daniel Donauer / Noëlle Ulrich, Die Vermarktung von Kosmetika, in: Jusletter, 13. Mai 2024- DE
- Daniel Donauer
- Noëlle Ulrich
Patent Litigation 2024 Switzerland – Trends and Developments
Chambers and Partners, Global Practice Guides, Patent Litigation 2024, February 15, 2024- EN
Firm News
MLL Legal successfully represented the Swiss retailer COOP on appeal in EPO opposition proceedings
MLL Legal represented Bayer Intellectual Property GmbH in a successful appeal before the Swiss Federal Supreme Court
MLL Legal defended Bristol-Myers Squibbs’ Supplementary Protection Certificate for apixaban
MLL Legal advises ADMETOS on the sale of ABC Dental AG, a full-service Swiss dental distributor
MLL Legal advised owner of Vio Chemicals
News Portal
E-cigarettes/vapes: Regulation and taxation are being tightened
1.—Swiss tobacco product law 1.1—(Current) Qualifying features in Swiss tobacco law Due to the (still) existing peculiarities within Swiss tobacco law, the requirements for tobacco products are derived from food law, specifically from the Federal Act on Foodstuffs and Utility Articles (Foodstuffs Act, oFSA) of 9 October 1992. Accordingly, tobacco products form a sub-segment of […]
More
Swiss database for medical devices (swissdamed) from Swissmedic
Switzerland has comprehensively revised its regulation for medical devices and in vitro diagnostic medical devices in order to improve safety and quality and to align with EU regulations. Due to the failure to update the Mutual Recognition Agreement (MRA), Switzerland has been considered a third country in the area of medical devices since May 2021 and in the area of in vitro diagnostic medical devices since May 2022. In response to this, the swissdamed database was set up to ensure market surveillance and guarantee the supply of safe products in Switzerland.
More
Developments regarding drinking water contamination by PFAS in Switzerland
In the EU and Switzerland, developments are currently underway regarding the maximum levels of PFAS (per- and polyfluorinated substances) in drinking water. Any tightening of food legislation is expected to have to be complied with from 2026.
More
European Reforms and Swiss Medtech: New Legislative Amendment on 1 November 2023 About Medical Devices That Have Non-medical Purpose
More than two years have passed after the breakdown of negotiations between Switzerland and the European Union (hereinafter: EU), followed by the set of new European regulations with the primary objective of enhancing the safety standards for medical devices. Switzerland has had to constantly adapt its legislation in this area to align with the heightened standards imposed by the EU.
More
Swiss Regulatory Framework for the Sale of E-Cigarettes (Vapes) Today and Under the New Tobacco Products Act as of 2024
Due to numerous new forms of consumption, the tobacco market has changed in recent years. New products such as electronic cigarettes (e-cigarettes), disposable vapes and other nicotine-containing products for oral use are now available to consumers as alternatives to conventional (nicotine-containing) cigarettes and are one of the reasons why the number of cigarette packs sold in Switzerland is declining. These alternative products are becoming increasingly popular.
MoreUpdate Your Browser
This website cannot be displayed correctly because you are using Internet Explorer. For optimal viewing and security, please use Chrome, Firefox or Edge.
